Onyx Bridge Wealth Group’s Akebia Therapeutics AKBA Stock Holding History

Onyx Bridge Wealth Group’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.4K	Buy	15,300 +300	+2%	+$357	﹤0.01%	385
2026 Q1	$20.9K	Hold	15,000	–	–	﹤0.01%	370
2025 Q4	$24.1K	Hold	15,000	–	–	﹤0.01%	363
2025 Q3	$41K	Hold	15,000	–	–	﹤0.01%	362
2025 Q2	$54.6K	Hold	15,000	–	–	0.01%	310
2025 Q1	$28.8K	Hold	15,000	–	–	﹤0.01%	289
2024 Q4	$28.5K	Hold	15,000	–	–	﹤0.01%	281
2024 Q3	$19.8K	Hold	15,000	–	–	﹤0.01%	282
2024 Q2	$15.3K	Hold	15,000	–	–	﹤0.01%	270
2024 Q1	$20.1K	Buy	15,000 +2,500	+20%	+$4K	﹤0.01%	259
2023 Q4	$15.5K	Hold	12,500	–	–	﹤0.01%	249
2023 Q3	$14.3K	Hold	12,500	–	–	﹤0.01%	234
2023 Q2	$11.4K	Hold	12,500	–	–	﹤0.01%	235
2023 Q1	$7K	Hold	12,500	–	–	﹤0.01%	185
2022 Q4	$8.03K	Hold	12,500	–	–	﹤0.01%	183
2022 Q3	$4K	Hold	12,500	–	–	﹤0.01%	171
2022 Q2	$5K	Buy	+12,500	New	+$5.25K	﹤0.01%	164

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Onyx Bridge Wealth Group's AKBA Position: Q2 2026 in Review

Onyx Bridge Wealth Group increased its Akebia Therapeutics (AKBA) stake by 2% in Q2 2026, buying an estimated $357 and bringing the position to 15,300 shares worth $17.4K. The position accounts for ﹤0.01% of the portfolio, ranked #385.

Onyx Bridge Wealth Group first reported a position in AKBA in Q2 2022 and has held it in 17 quarters since. The position peaked at $54.6K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Onyx Bridge Wealth Group held 15,300 shares of Akebia Therapeutics worth $17.4K as of Q2 2026.
Onyx Bridge Wealth Group bought 300 Akebia Therapeutics shares in Q2 2026, an estimated $357.
Akebia Therapeutics made up ﹤0.01% of Onyx Bridge Wealth Group's portfolio in Q2 2026, its #385 holding.
Onyx Bridge Wealth Group first reported a position in Akebia Therapeutics in Q2 2022 and has held it in 17 quarters since.
Onyx Bridge Wealth Group's Akebia Therapeutics position peaked at $54.6K in Q2 2025.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Onyx Bridge Wealth Group's 13F filing for Q2 2026, filed 23 Jul 2026.